Selected article for: "arterial thromboembolism and ATE arterial thromboembolism"
Author: Pavoni, Vittorio; Gianesello, Lara; Horton, Andrew
Title: Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
  • Cord-id: o24cwg6c
  • Document date: 2021_5_10
    • ID: o24cwg6c
    Snippet: Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid ant
    Document: Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease.

    Search related documents:
    Co phrase search for related documents
    • activity level and acute phase: 1, 2, 3, 4, 5
    • activity level and long term follow: 1, 2
    • acute distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute distress syndrome and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute distress syndrome and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute myocardial infarction and lmwh weight heparin: 1, 2
    • acute myocardial infarction and long term follow: 1, 2, 3
    • acute myocardial infarction and long term follow need: 1
    • acute myocardial infarction and low molecular lmwh weight heparin: 1, 2
    • acute phase and lmwh weight heparin: 1, 2
    • acute phase and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute phase and long term follow need: 1
    • acute phase and low molecular lmwh weight heparin: 1, 2
    • lmwh weight heparin and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25